• $7,500,000 standby equity capital over 5 years
• Cynata has full discretion on utilization, timing, and pricing
• No restrictions on raising capital through other methods

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced that it has entered into an At-the-Market Subscription Agreement ('ATM') with Acuity Capital. The ATM provides Cynata with up to $7,500,000 of standby equity capital over the coming five years, to 31 July 2030. Importantly, Cynata has full discretion as to whether or not to utilise the ATM, the maximum number of shares to be issued, the minimum issue price of shares and the timing of each subscription (if any). There are no requirements on Cynata to utilise the ATM and Cynata may terminate the ATM at any time, without cost or penalty. Neither Acuity Capital nor the ATM place any restrictions at any time on Cynata raising capital through other methods. If Cynata does decide to utilise the ATM, Cynata is able to set an issue price floor at its sole discretion, with the final issue price being calculated as the greater of the nominated floor price and up to a 10% discount to a Volume Weighted Average Price ('VWAP') over a period of Cynata's choosing (again at its sole discretion). Acuity Capital is not obliged to subscribe for shares if or when requested by Cynata. As security for the ATM, the Company has agreed to place 11,500,000 fully paid ordinary shares in the Company from its Listing Rule 7.1 capacity at nil cash consideration to Acuity Capital. Upon early termination or maturity of the ATM, the Company may buy back (and cancel) the shares placed as security for no cash consideration (subject to shareholder approval).